Discovery of a Peptide-Based Renin Inhibitor with Oral Bioavailability and Efficacy

Peptidic renin inhibitors have been poorly absorbed across the intestine or rapidly eliminated by the liver and have been reported to have oral bioavailabilities of less than 2%. A peptide-based renin inhibitor, A-72517 (molecular mass of 706 daltons), was devised that has oral bioavailabilities of...

Ausführliche Beschreibung